Jury Hands AstraZeneca Win In Nexium Pay-For-Delay Case
By Melissa Lipman ( December 5, 2014, 2:29 PM EST) -- A Massachusetts federal jury sided with defendants AstraZeneca PLC and Ranbaxy Inc. in the first pay-for-delay class action trial since the U.S. Supreme Court agreed the patent settlements could face antitrust scrutiny, finding that AstraZeneca would never have allowed a generic Nexium to launch before its medicine patents expired....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.